CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment

Journal of the Neurological Sciences

Volumn 251, Issue 1-2, 2006, Pages 124-128

  Stefani, Alessandro ^a,b   Martorana, Alessandro ^a,b   Bernardini, Sergio ^d   Panella, Marta ^b   Mercati, Flavio ^c   Orlacchio, Antonio ^a,b   Pierantozzi, Mariangela ^b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITÀ DI ROMA LA SAPIENZA   (Italy)

^d TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; Beta amyloid; MMSE; Pseudo dementia; Stage markers; Tau protein

Indexed keywords

TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STANDARDIZATION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 33751212726     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.09.014     Document Type: Article

References (37)

1. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5 (2004) 677-685
2. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer Disease. Neurology 34 (1984) 939-944
3. Pierantozzi M., Panella M., Palmieri M.G., Koch G., Giordano A., Marciani M.G., et al. Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia. Clin Neurophysiol 115 (2004) 2410-2418
4. Blennow K., and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2 (2003) 605-613
5. Parnetti L., Lanari A., Saggese E., Spaccatini C., and Gallai V. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice. Neurol Sci 24 (2003) 199-200
6. Schoonenboom N.S., Pijnenburg Y.A., Mulder C., Rosso S.M., Van Elk E.J., Van Kamp G.J., et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62 (2004) 1580-1584
7. Stefani A., Bernardini S., Panella M., Pierantozzi M., Nuccetelli M., Koch G., et al. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. J Neurol Sci 237 (2005) 83-88
8. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 289 (2003) 2094-2103
9. Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., and Blennow K. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59 (2003) 1729-1734
10. Hampel H., Teipel S.J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9 (2004) 705-710
11. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5 (2006) 228-234
12. Herukka S.K., Hallikainen M., Soininen H., and Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64 (2005) 1294-1297
13. Ivanoiu A., and Sindic C.J. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase 11 1 (Feb 2005) 32-39
14. Riemenschneider M., Lautenschlager N., Wagenpfeil S., Diehl J., Drzezga A., and Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59 11 (Nov 2002) 1729-1734
15. Ganzer S., Arlt S., Schoder V., Buhmann C., Mandelkow E.M., Finckh U., et al. CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity. J Neural Transm 10 (2003) 1149-1160
16. Prince J.A., Zetterberg H., Andreasen N., Marcusson J., and Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 62 (2004) 2116-2118
17. Riemenschneider M., Schmolke M., Lautenschlager N., Vanderstichele H., Vanmechelen E., and Guder W.G. Association of CSF apolipoprotein E, Abeta42 and cognition in Alzheimer's disease. Neurobiol Aging 23 (2002) 205-211
18. Buerger K., Teipel S.J., Zinkowski R., Blennow K., Arai H., Engel R., et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59 4 (Aug 27 2002) 627-629
19. Carlesimo G.A., Caltagirone C., and Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration battery. Eur Neurol 36 (1996) 378-384
20. Wahlund O., et al., On behalf of the European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and TC. Stroke 32 (2001) 1318-1322
21. Vandermeeren M., Mercken M., Vanmechelen E., Six J., van de Voorde A., Martin J.J., et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 61 (1993) 1828-1834
22. Vanderstichele H., Van Kerschaver E., Hesse C., Davidsson P., Buyse M.A., Andreasen N., et al. Standardization of measurement of beta-amyloid (1-42) in cerebrospinal fluid and plasma. Amyloid 7 (2000) 245-258
23. Maruyama M., Arai H., Sugita M., Tanji H., Higuchi M., Okamura N., et al. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 172 (2001) 433-436
24. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38 (1995) 643-648
25. Samuels S.C., Silverman J.M., Marin D.B., Peskind E.R., Younki S.G., Greenberg D.A., et al. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology 52 (1999) 547-551
26. Jack Jr. C.R., Dickson D.W., Parisi J.E., Xu Y.C., Cha R.H., O'Brien P.C., et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 58 (2002) 750-757
27. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
28. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 (2003) 409-421
29. Billings L.M., Oddo S., Green K.N., McGaugh J.L., and Laferla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005) 675-688
30. Selkoe D.J., and Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43 (2003) 545-584
31. Buttini M., Yu G.Q., Shockley K., Huang Y., Jones B., Masliah E., et al. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci 22 (2002) 10539-10548
32. Trinchese F., Liu S., Battaglia F., Walter S., Mathews P.M., and Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 55 (2004) 801-814
33. Moonies M., Swearer J.M., Dayaw M.P.E., St George-Hyslop P., Rogaeva E., Kawarai T., et al. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Ann Neurol 58 (2005) 748-757
34. Clark C.M., Sharon X., Chittams J., Ewbank D., Peskind E., Galasko D., et al. Cerebrospinal fluid tau and b-amyloid. How well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 60 (2003) 1696-1702
35. Abdi F., Quinn J.F., Jankovic J., McIntosh M., Leverenz J.B., Peskind E., et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9 (2006) 293-348
36. Biroccio A., Del Boccio P., Panella M., Bernardini S., Di Ilio C., Gambi D., et al. Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Proteomics 6 (2006) 2305-2313
37. Iqbal K., Flory M., Khatoon A., Soinonen H., and Pirttila T. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 58 (2005) 748-757